The export of key generic pharmaceutical products. To secure this stock, the Indian Government has recently temporarily restricted Per cent of its APIs originating from China. Vulnerable to disruption in Chinese API manufacturing, given it sources over 70 The global drug supply chain could be significant. To say, the risk that COVID-19-related factory closures pose to The World Health Organisation (WHO) estimated that China accounted for some 20 per cent of the total global output of APIs in 2016 and it has risen since. Prior to the crisis, China was on its way to becoming a leading global pharmaceutical powerhouse, the COVID-19 will have undoubtedly impacted its API manufacturing growth, although recovery is now under way. Chinese and Indian APIs are the basis of many mass market generic medicines, including those now treating the symptoms of COVID-19 such as paracetamol, antibiotics and respiratory medicines. As such, the COVID-19 pandemic has raised questions as to the resilience of the network as many Active Pharmaceutical Ingredients (APIs) are increasingly manufactured in China. Over the past decade, the medicines supply chain has become an increasingly integrated global network. Until a vaccine is available, therapies licensed for other indications, but not COVID-19, are being put into accelerated clinical trials as potential treatments for the virus. This will serve to protect the integrity of the supply chain of medicines needed to treat the virus, once those treatments have been approved.įurther to this, the life sciences industry is responding to the changing work patterns of regulators who are working to fast track potential treatments and rapidly evaluate their impact through real-world evidence. IQVIA, the Human Data Science company which provides advanced analytics, technology solutions and contract research solutions to the healthcare ecosystem, is already delivering daily medicines supply chain data insights at national and local level to the UK Government. This of course extends beyond vaccine development. Indeed, across the world the industry has risen to the challenge by rapidly mobilising support for healthcare systems and professionals with the speed and capabilities at its disposal. In the short term, healthcare resources are being massively diverted towards responding to the COVID-19 pandemic. Patterns of healthcare providers will change beyond recognition. Space must respond to a rapidly changing landscape and market dynamics. Pharma and biotech sectors have a vital role to play. Hospital Times Editor David Duffy tuned into an IQVIA webinar, hosted by Pharmaphorum, to ascertain just how the global pharma and biotech sectors are adjusting to this global crisis.ĬOVID-19 tightens its grip on health systems and economies around the world, the global
0 kommentar(er)
